Scalper1 News
The past few years have brought some groundbreaking drug launches, such as the record-breaking Gilead Sciences rollout of its hepatitis C medicines and the first PD-1 cancer fighters from Merck and Bristol-Myers Squibb (BMY). This year, though, looks to be somewhat slower on that front. Drug firms will aim most of their new launches at smaller markets or will build on existing franchises. Still, Merck (MRK), Gilead Sciences (GILD) and Eli Lilly Scalper1 News
Scalper1 News